Expression of SOX11 and HER2 and their association with recurrent breast cancer

Wang, Fuwen; Ao, Xiang; Fu, Shao-Mei

doi:10.21037/tcr.2019.01.27

Cited by 3 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is the most commonly diagnosed cancer (11.6%) and the leading cause of cancer death (6.6%) among females worldwide ( 1 ). Different subtypes of breast cancer have distinct risk profiles and prognosis ( 2 ). Approximately 20% of breast cancer patients are human epidermal growth factor 2 (HER2)-positive, which was known to have a poorer prognosis before the development of targeted therapies ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

Xia¹,

Zheng²,

Xiang³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Breast cancer recurrence and mortality have been shown to decrease after trastuzumab treatment in human epidermal growth factor 2 (HER2)-positive early-stage breast cancer (EBC) patients. In Jiangsu Province, trastuzumab has been subsidized for patients with HER2-positive EBC since 2013. Several studies showed that Jiangsu was one of the provinces with the highest rates of adjuvant trastuzumab therapy.To uncover the underlying reason, we designed the study to investigate trastuzumab use for HER2-positive breast cancer patients, and to examine the changes caused by medical insurance coverage for trastuzumab in Jiangsu province of China.Methods: This was a retrospective, multicenter clinical study with follow-up data. HER2-positive EBC patients diagnosed in 7 representative hospitals in 2010, 2011, and 2013 were enrolled. Demographic and clinical data, and details of diagnosis, treatments, and prognosis, were collected. Data analysis included univariate analysis, multivariate logistic regression, survival analysis, and subgroup analysis.Results: Of the 641 patients (mean age 51.01±10.79 years) included, 412 (64.27%) patients had medical insurance. Trastuzumab therapy was given to 214 (33.39%) patients. The multivariate logistic regression showed that medical insurance coverage, age, and radiotherapy were associated with trastuzumab use (P<0.05).The overall survival was significantly better in the trastuzumab group than in the non-trastuzumab group (HR: 1.607; 95% CI: 1.046-2.469; P=0.040). Subgroup analysis revealed that there was a trend towards more patients with medical insurance (P=0.073), and significantly more patients received trastuzumab therapy (P<0.001) in 2013 than in 2010-2011. Additionally, trastuzumab use in China was lower than in developed countries. Patients with medical insurance were more likely to use trastuzumab, and more patients could afford trastuzumab therapy with the development of China's health-care reform.Conclusions: Our study suggested that the percentage of patients who received trastuzumab in China was lower than developed countries. Patients who had medical insurance were more likely to use trastuzumab than those without medical insurance. The health insurance policy in China has improved access for breast cancer patients who require trastuzumab therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

Xia¹,

Zheng²,

Xiang³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Previous studies demonstrated that SOX11 was highly expressed in the central nervous system, gastrointestinal tract, lung, spleen, pancreas, kidney and gonads in normal humans [ 12 , 13 , 14 ]. SOX11 was reported to be highly expressed in breast cancer [ 17 ], mantle cell lymphoma [ 18 ], epithelial ovarian cancer [ 19 ] and hepatocellular carcinoma [ 20 ], while it was expressed at low levels in nasopharyngeal carcinoma [ 21 ], prostate cancer [ 22 ], gastric cancer (GC) [ 23 ] and bladder cancer [ 24 ]. However, we discovered that SOX11 expression was altered in 27 cancer tissues from the TCGA database compared to normal tissues.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown that the expression levels of SOX11 vary in different cancer types. For example, a high level of SOX11 mRNA can be detected in many types of tumors, including breast cancer [ 17 ], mantle cell lymphoma [ 18 ], epithelial ovarian cancer [ 19 ] and hepatocellular carcinoma [ 20 ]. In contrast, a low expression of SOX11 was frequently observed in other cancers, such as nasopharyngeal carcinoma (NPC) [ 21 ], prostate cancer [ 22 ], gastric cancer (GC) [ 23 ] and bladder cancer [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Systematic Investigation of the Multifaceted Role of SOX11 in Cancer

Sun

Dong

et al. 2022

Cancers

View full text Add to dashboard Cite

SRY-box transcription factor 11 (SOX11), as a member of the SOX family, is a transcription factor involved in the regulation of specific biological processes and has recently been found to be a prognostic marker for certain cancers. However, the roles of SOX11 in cancer remain controversial. Our study aimed to explore the various aspects of SOX11 in pan-cancer. The expression of SOX11 was investigated by the Genotype Tissue-Expression (GTEX) dataset and the Cancer Genome Atlas (TCGA) database. The protein level of SOX11 in tumor tissues and tumor-adjacent tissues was verified by human pan-cancer tissue microarray. Additionally, we used TCGA pan-cancer data to analyze the correlations among SOX11 expression and survival outcomes, clinical features, stemness, microsatellite instability (MSI), tumor mutation burden (TMB), mismatch repair (MMR) related genes and the tumor immune microenvironment. Furthermore, the cBioPortal database was applied to investigate the gene alterations of SOX11. The main biological processes of SOX11 in cancers were analyzed by Gene Set Enrichment Analysis (GSEA). As a result, aberrant expression of SOX11 has been implicated in 27 kinds of cancer types. Aberrant SOX11 expression was closely associated with survival outcomes, stage, tumor recurrence, MSI, TMB and MMR-related genes. In addition, the most frequent alteration of the SOX11 genome was mutation. Our study also showed the correlations of SOX11 with the level of immune infiltration in various cancers. In summary, our findings underline the multifaceted role and prognostic value of SOX11 in pan-cancer.

show abstract

Classification and immune invasion analysis of breast cancer based on m6A genes

Qin¹,

Fang²,

Zhou³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Breast cancer (BRCA) shows genetic, epigenetic, and phenotypic diversity. Methylation of N6-methyladenosine (m6A) affects the occurrence, development, and therapeutic efficacy of BRCA.However, the characteristics and prognostic value of m6A in BRCA remain unclear. We aimed to classify and construct a scoring system for the m6A regulatory gene in BRCA, and to explore its potential mechanisms.Methods: In this study, we selected 23 m6A regulatory genes and analyzed their genetic variation in BRCA, including copy number variation (CNV) data, expression differences, mutations, gene types, and correlations between genes. Survival curves were drawn by the Kaplan-Meier method, and a log-rank P<0.05 was considered statistically significant. The partitioning around medoids (PAM) algorithm was used for molecular subtype analysis of m6A, single-sample Gene Set Enrichment Analysis (ssGSEA) algorithm was used to quantify the relative infiltration levels of various immune cell subgroups, and a scoring system was built based on principal component analysis (PCA).Results: In BRCA, m6A regulatory gene mutation frequency is not high, while that of CNV mutation is high, which is related to gene expression and closely related to prognosis. In this study, we identified 3 different m6A subtypes, which are closely related to the level of immune cell infiltration. We further constructed an m6A score system, in which lower scores were correlated with low tumor mutation burden (TMB), later clinical staging, programmed cell death 1 ligand 1 (PD-L1) expression, and triple-negative breast cancer (TNBC). Conclusions: This study highlights the diversity and complexity of the role of m6A in BRCA. The classification of BRCA based on the m6A regulatory gene can help us understand the characteristics of BRCA and help develop individualized immunotherapy regimens.

show abstract

Expression of SOX11 and HER2 and their association with recurrent breast cancer

Cited by 3 publications

References 28 publications

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

Systematic Investigation of the Multifaceted Role of SOX11 in Cancer

Classification and immune invasion analysis of breast cancer based on m6A genes

Contact Info

Product

Resources

About